We consider the validity and accuracy of information in medical science as it relates to legal liability. We argue that fundamental changes have occurred concerning knowledge dissemination to doctors (and patients) that have profound implications for the ethical and legal responsibility for accuracy. Such considerations are important for legal professionals at all stages of legal processes and tribunal proceedings.
AdamsonJAliSSanthouseA, et al. (2020) Cognitive behavioural therapy for chronic fatigue and chronic fatigue syndrome: Outcomes from a specialist clinic in the UK. Journal of the Royal Society of Medicine113(10): 394–402.
2.
AhmedSAMewesJCVrijhoefH (2020) Assessment of the scientific rigour of randomized controlled trials on the effectiveness of cognitive behavioural therapy and graded exercise therapy for patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review. Journal of Health Psychology25(2): 240–255.
3.
AltmanDG (1994) The scandal of poor medical research. BMJ308(6924): 283–284.
4.
AndradeCSarkhelS (2025) Guidelines are merely guidelines. Indian Journal of Psychiatry67(3): 281–282.
AshcroftRE (2004) Current epistemological problems in evidence based medicine. Journal of Medical Ethics30(2): 131–135.
7.
Baker v. Arbor Drugs I (1993) Michigan Appellate reports; North Western Reporter, 2D Series 215 Mich. App.; 488 N.W.482d (Michigan Court of Appeals 1993).
8.
BastianH (2016) Nondisclosure of financial interest in clinical practice guideline development: An intractable problem?PLoS Medicine13(5): e1002030.
9.
BerwickDM (2005) Broadening the view of evidence-based medicine. Quality & Safety in Health Care14(5): 315–316.
CampsallPColizzaKStrausS, et al. (2016) Financial relationships between organizations that produce clinical practice guidelines and the biomedical industry: A cross-sectional study. PLoS Medicine13(5): e1002029.
12.
CartwrightN (2007) Are RCTs the gold standard?BioSocieties2(1): 11–20.
13.
CartwrightN (2011) A philosopher's view of the long road from RCTs to effectiveness. The Lancet377(9775): 1400–1401.
14.
CartwrightN (2018) What evidence should guidelines take note of?Journal of Evaluation in Clinical Practice24(5): 1139–1144.
15.
ChavalariasDWallachJDLiAH, et al. (2016) Evolution of reporting P values in the biomedical literature, 1990–2015. JAMA315(11): 1141–1148.
16.
ChiewALBuckleyNA (2022) The serotonin toxidrome: Shortfalls of current diagnostic criteria for related syndromes. Clinical Toxicology (Phila)60(2): 143–158.
17.
CohenJSInselPA (1996) The Physicians’ Desk Reference. Problems and possible improvements. Archives of Internal Medicine156(13): 1375–1380.
18.
CromieBW (1963) The feet of clay of the double-blind trial. The Lancet2(7315): 994–997.
19.
CulbertsonVLRahmanSEBosenGC, et al. (2018) Implications of off-target serotoninergic drug activity – An analysis of serotonin syndrome reports using a systematic bioinformatics approach. Pharmacotherapy38(9): 888–898.
20.
DavidsonKWSilversteinMCheungK, et al. (2021) Experimental designs to optimize treatments for individuals. JAMA Pediatrics175(4): 404.
21.
DeAngelisCDFontanarosaPB (2008) Impugning the integrity of medical science: The adverse effects of industry influence. JAMA299(15): 1833–1835.
22.
FlaccoMEManzoliLBocciaS, et al. (2015) Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. Journal of Clinical Epidemiology68(7): 811–820.
23.
GaniILitchfieldIShuklaD, et al. (2025) Understanding ‘alert fatigue’ in primary care: Qualitative systematic review of general practitioners attitudes and experiences of clinical alerts, prompts, and reminders. Journal of Medical Internet Research27: e62763.
24.
GeraghtyKJ (2017) PACE-Gate': When clinical trial evidence meets open data access. Journal of Health Psychology22(9): 1106–1112.
25.
GillCJSabinLSchmidCH (2005) Why clinicians are natural Bayesians. BMJ330(7499): 1080–1083.
26.
GillmanPK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia95(4): 434–441.
27.
GillmanPK (2006a) A review of serotonin toxicity data: Implications for the mechanisms of antidepressant drug action. Biological Psychiatry59(11): 1046–1051.
28.
GillmanPK (2006b) A systematic review of the serotonergic effects of mirtazapine: Implications for its dual action status. Human Psychopharmacology. Clinical and Experimental21(2): 117–125.
GillmanPK (2025) Monoamine oxidase inhibitors: A paradigm of poor science. Journal of Psychopharmacology39: 1335–1337. doi:10.1177/02698811251381762. 2698811251381762.
31.
GoyalPSaffordMMHilmerSN, et al. (2022) N-of-1 trials to facilitate evidence-based deprescribing: Rationale and case study. British Journal of Clinical Pharmacology88(10): 4460–4473.
32.
GreenlandSSennSJRothmanKJ, et al. (2016) Statistical tests, P values, confidence intervals, and power: A guide to misinterpretations. European Journal of Epidemiology31(4): 337–350.
33.
HarveySBWadsworthMWesselyS, et al. (2008) The relationship between prior psychiatric disorder and chronic fatigue: Evidence from a national birth cohort study. Psychological Medicine38(7): 933–940.
34.
HillAB (1966) Reflections on controlled trial. Annals of the Rheumatic Diseases25(2): 107–113.
35.
HurwitzB (1999) Legal and political considerations of clinical practice guidelines. BMJ318(7184): 661–664.
36.
HurwitzB (2004) How does evidence based guidance influence determinations of medical negligence?BMJ329(7473): 1024–1028.
37.
IoannidisJP (2016) The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. The Milbank Quarterly94(3): 485–514.
38.
IoannidisJPA (2019) Cochrane crisis: Secrecy, intolerance and evidence-based values. European Journal of Clinical Investigation49(3): e13058.
39.
JelinekGANeateSL (2009) The influence of the pharmaceutical industry in medicine. Journal of Law and Medicine17(2): 216.
40.
KhouriCHlavatyAFusaroliM, et al. (2025) The rising misuse of pharmacovigilance reporting systems: A threat to evidence-based medicine. Clinical Pharmacology and Therapeutics119(2): 318–321. doi:10.1002/cpt.70180.
41.
KungJMillerRRMackowiakPA (2012) Failure of clinical practice guidelines to meet institute of medicine standards: Two more decades of little, if any, progress. Archives of Internal Medicine172(21): 1628–1633.
42.
LasagnaL (1973) The efficacy of self-medication, philosophy and technology of drug assessment discussion. Smithsonian Institution, Washington, DC: Joseph D. Cooper, ed., 168: 156.
43.
LasagnaL (1975) Clinical trials of drugs from the viewpoint of the academic investigator (a satire). Clinical Pharmacology and Therapeutics18(5 Pt 2): 629–633.
44.
LeaASKhuranaJK (2025) Medical reference tools and pharmaceutical promotion: A history of entanglement. Annals of Internal Medicine178(2): 279–284.
45.
LiXWenXFuH, et al. (2025) Drug-associated serotonin syndrome in elderly patients: A comprehensive disproportionality analysis based on the FAERS database. Frontiers in Pharmacology16(16): 1700469..
46.
MarksDF (2022) The rise and fall of the psychosomatic approach to medically unexplained symptoms, myalgic encephalomyelitis and chronic fatigue syndrome. Archives of Epidemiology & Public Health Research1(2): 97–143.
47.
McGrayneSB (2011) The Theory that would Not Die: How Bayes’ Rule Cracked the Enigma Code. Yale University Press.
MullenWHAndersonIBKimSY, et al. (1997) Incorrect overdose management advice in the Physicians’ Desk Reference. Annals of Emergency Medicine29(2): 255–261.
NuttDJ (2020) Groundhog Decade not Brave New World. London, England: Sage Publications UK, 1–6. 2050324519898963.
52.
ParkerGBGrahamRKTavellaG (2017) Is there consensus across international evidence-based guidelines for the management of bipolar disorder?Acta Psychiatrica SCAndinavica135(6): 515–526.
53.
PearlJ (2014) Interpretation and identification of causal mediation. Psychological Methods19(4): 459–481.
54.
PollockDBarkerTHStoneJC, et al. (2024) Predatory journals and their practices present a conundrum for systematic reviewers and evidence synthesisers of health research: A qualitative descriptive study. Research Synthesis Methods15(2): 257–274.
55.
PorcinoAVohraS (2022) N-of-1 trials, their reporting guidelines, and the advancement of open science principles. Harvard Data Science Review4(SI3). 10.1162/99608f99692. a99665a99257a.
56.
RaczRSoldatosTJacksonD, et al. (2018) Association between serotonin syndrome and second-generation antipsychotics via pharmacological target-adverse event analysis. Clinical and Translational Science11(3): 322–329.
57.
RawlinsM (2008) De testimonio: On the evidence for decisions about the use of therapeutic interventions. The Lancet372(9656): 2152–2161.
58.
RichtigGBergerMKoellerM, et al. (2023) Predatory journals: Perception, impact and use of Beall's list by the scientific community – A bibliometric big data study. PLoS One18(7): e0287547.
59.
Secretary of Health (1997) The New NHS. London: Stationery Office(Cm 3807).
60.
SelkerHPDulkoDGreenblattDJ, et al. (2023) The use of N-of-1 trials to generate real-world evidence for optimal treatment of individuals and populations. Journal of Clinical and Translational Science7(1): e203.
61.
SienaLMPapamanolisLSiebertMJ, et al. (2023) Industry involvement and transparency in the most cited clinical trials, 2019–2022. JAMA Network Open6(11): e2343425.
62.
SolomonM (2011) Just a paradigm: Evidence-based medicine in epistemological context. European Journal for Philosophy of Science1(3): 451.
63.
SpiegelhalterDJMylesJPJonesDR, et al. (1999) Methods in health service research. An introduction to Bayesian methods in health technology assessment. British Medical Journal319(7208): 508–512.
64.
StunnenbergBCBerendsJGriggsRC, et al. (2022) N-of-1 trials in neurology: A systematic review. Neurology98(2): e174–e185.
65.
SzigetiBPhillipsLDNuttD (2023) Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins. British Journal of Clinical Pharmacology89(9): 2646–2648.
66.
ThomaMFroehlichLHattesohlDBR, et al. (2024) Why the psychosomatic view on myalgic encephalomyelitis/chronic fatigue syndrome is inconsistent with current evidence and harmful to patients. Medicina60: 83–92. 10.3390/medicina60010083.
67.
TrayerJRowbothamNJBoyleRJ, et al. (2022) Industry influence in healthcare harms patients: Myth or maxim?Breathe (Sheff)18(2). 10.1183/20734735.20730010-20732022.
68.
VinkMVink-NieseA (2022) The updated NICE guidance exposed the serious flaws in CBT and graded exercise therapy trials for ME/CFS. Healthcare10: 898–921.
69.
VinkersCHLamberinkHJTijdinkJK, et al. (2021) The methodological quality of 176,620 randomized controlled trials published between 1966 and 2018 reveals a positive trend but also an urgent need for improvement. PLoS Biology19(4): e3001162.
70.
WhitePAbbeySAngusB, et al. (2023) Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis. Journal of Neurology Neurosurgery & Psychiatry94(12): 1056–1063.
71.
WilmontILoeffenMHoogeboomT (2024) A qualitative study on the facilitators and barriers to adopting the N-of-1 trial methodology as part of clinical practice: Potential versus implementation challenges. International Journal of Qualitative Studies on Health and Well-Being19(1): 2318810.
